trending Market Intelligence /marketintelligence/en/news-insights/trending/U_a1XADP2KPon8OlRxokcg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Approvals for AstraZeneca, Merck & Co.; designations for UroGen, Pfizer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Approvals for AstraZeneca, Merck & Co.; designations for UroGen, Pfizer

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Dec. 20.

Approvals

* AstraZeneca PLC and Daiichi Sankyo Co. Ltd.'s Enhertu, for HER2-positive breast cancer that has spread across the body or has metastasized after receiving two or more therapies.

* Merck & Co. Inc.'s Ervebo, for preventing Ebola virus disease.

* Pfizer Inc. and Astellas Pharma Inc.'s Xtandi for metastatic castration-sensitive prostate cancer.

* Seattle Genetics Inc. and Astellas Pharma's Padcev for adult patients with locally advanced or spreading urothelial cancer who have not responded to a PD-1/L1 inhibitor and platinum-containing chemotherapy.

* Avadel Pharmaceuticals PLC's Nouress injection for neonatal patients that require total parenteral nutrition.

* Medtronic PLC's Stealth Autoguide robotic system for positioning assistance during neurosurgical procedures.

* Elekta AB (publ)'s Elekta Unity technology in diffusion-weighted imaging.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* UroGen Pharma Ltd.'s UGN-101, for low-grade upper tract urothelial cancer.

* Pfizer's Braftovi, in combination with Eli Lilly and Co.'s Erbitux for its expanded use in treating patients with BRAF-mutant colorectal cancer who have received either one or two prior therapies.

Fast track

* Kura Oncology Inc.'s tipifarnib for patients with HRAS mutant head and neck squamous cell carcinomas after progression on platinum therapy.

* Salarius Pharmaceuticals Inc.'s seclidemstat for Ewing sarcoma.

Breakthrough therapy

* Agios Pharmaceuticals Inc.'s Tibsovo for relapsed or refractory myelodysplastic syndrome that have a mutation called isocitrate dehydrogenase 1, or IDH1.

* Seattle Genetics' tucatinib, in combination with Roche Holding AG's Herceptin and Xeloda for HER2-positive breast cancer patients whose disease has spread to nearby tissue or lymph nodes and cannot be surgically removed or has spread to other parts of the body.

Other designations

* Orphan drug, for Eagle Pharmaceuticals Inc.'s Ryanodex for organophosphate exposure.

* Orphan drug, for Prevail Therapeutics Inc.'s gene therapy PR006 for frontotemporal dementia patients with a GRN gene mutation.

* Orphan drug, for Cytokinetics Inc.'s reldesemtiv for amyotrophic lateral sclerosis.